Immuron Ltd
IMRNImmuron Ltd in brief
Immuron Ltd is a listed company in the Biotechnology industry, based in Australia. Its market value was $9 M on 1 August 2026, which makes it the 26,015th largest listed company in the world and the 737th largest in Australia on this site. In the year to June 2025 it had sales of $5 M and a net loss of $3 M. Steven George Lydeamore is its chief executive. Its largest product and service lines by sales in 2026 were Travelan (99%), ProIBS (1%) and Protectyn (under 1%). Its shares trade under the symbol IMRN (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Immuron Ltd
Immuron Limited was incorporated as an Australian Public Company, Limited by Shares under the name Anadis Limited (and changed its name to Immuron Limited in December 2008) in Victoria, Australia under the laws of the Commonwealth of Australia in 1994 and our ordinary shares have been listed on the ASX since April 30, 1999. Our ADSs and Warrants have traded on The NASDAQ Capital Market since June 13, 2017, with the Warrants delisted in June 2022 in connection with their expiration. We currently operate under the laws of the Commonwealth of Australia, including the Corporations Act of 2001. Our principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053 and our telephone number is +61 (0)3 8892 4854. Our agent for service in the U.S. is Puglisi & Associates, 850 Library Avenue, Suite 204, Newark, DE 19711. Our website address is www.immuron.com.au. The information contained on or accessible through our website is not a part of or incorporated by reference into this annual report and the inclusion of our website address herein is an inactive textual reference only.
From the company's annual report filed with the US SEC: read the report
Immuron Ltd timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔· approximateInitial public offering on Nasdaq
Events of Immuron Ltd from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Australia: #596 (Jan 2020) · #531 (Jan 2021) · #1,276 (Jan 2022) · #951 (Dec 2022) · #1,015 (Jul 2023) · #1,078 (Jan 2024) · #7 (Mar 2026) · #731 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.9×
- Price / book
- 1.7×
- Free cash flow yield
- -42.8%
- Net margin (TTM)
- -71.6%
- Operating margin
- -73.3%
- Return on equity
- -64.1%
- Liabilities / assets
- 20.4%
- Revenue growth
- +47.0%
- R&D / revenue
- 49.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Jun 2025 | $5M | +47.0% | $-3M | $-3M | -71.6% |
| Jun 2024 | $3M | +165.3% | $-4M | $-5M | -141.7% |
| Jun 2023 | $1M | +116.1% | $-2M | $-3M | -210.7% |
| Jun 2022 | $1M | +409.1% | $-2M | $-2M | -369.6% |
| Jun 2021 | $0M | -93.5% | $-6M | $-6M | -5681.8% |
| Jun 2020 | $2M | +17.4% | $-2M | $-2M | -116.0% |
| Jun 2019 | $1M | +27.4% | $-3M | $-3M | -231.3% |
| Jun 2018 | $1M | — | $-2M | $-2M | -210.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Jun 2025 | $-4M | — | — | $-1.46 | — |
| Jun 2024 | $-4M | $0M | $-4M | $-1.99 | — |
| Jun 2023 | $-2M | $0M | $-2M | $-1.12 | — |
| Jun 2022 | $-2M | $0M | $-2M | $-0.91 | — |
| Jun 2021 | $-3M | $0M | $-3M | $-2.83 | — |
| Jun 2020 | $-2M | $0M | $-2M | — | — |
| Jun 2019 | $-1M | $0M | $-1M | — | — |
| Jun 2018 | $-3M | $0M | $-3M | — | — |
SEC filings
- Nov 10, 20266-KReport of foreign issuer
- Oct 28, 20266-KReport of foreign issuer
- Oct 27, 20266-KReport of foreign issuer
- Oct 23, 20266-KReport of foreign issuer
- Oct 22, 20266-KReport of foreign issuer
- Oct 16, 20266-KReport of foreign issuer
- Oct 13, 20266-KReport of foreign issuer
- Sep 24, 202620-FAnnual report (foreign issuer) · period to Jun 2026
- Sep 24, 20266-KReport of foreign issuer
- Sep 22, 20266-KReport of foreign issuer
- Sep 4, 20266-KReport of foreign issuer
- Aug 28, 20266-KReport of foreign issuer
Official filings of Immuron Ltd with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-3 M
- Net income
- $-3 M
For year ending June-2025 · source: SEC filing
Balance sheet
- Total assets
- $7 M
- Total liabilities
- $1 M
- Total equity
- $5 M
As of June-2025
Top 8 institutional investors in Immuron Ltd#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BNP Paribas Financial Markets | 49,549 | +44,349 (+852.87%) | 0.59% | $0 M | Nov 12, 2026 |
| 2 | HRT Financial LP | 33,396 | +12,812 (+62.24%) | 0.40% | $0 M | Nov 13, 2026 |
| 3 | Jane Street Group, LLC | 33,255 | New | 0.40% | $0 M | Nov 12, 2026 |
| 4 | UBS Group AG | 22,512 | +22,149 (+6101.65%) | 0.27% | $0 M | Nov 10, 2026 |
| 5 | Citadel Advisors LLC | 14,690 | -28,433 (-65.93%) | 0.18% | $0 M | Nov 16, 2026 |
| 6 | Rhumbline Advisers | 3,835 | -3,532 (-47.94%) | 0.05% | $0 M | Nov 10, 2026 |
| 7 | Royal Bank Of Canada | 160 | New | 0.00% | $0 M | Nov 16, 2026 |
| 8 | Caitong International Asset Management Co., Ltd | 28 | New | 0.00% | $0 M | Oct 29, 2026 |
Markets and events: Immuron Ltd#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 217 shares at $0.91
- : 111 shares at $0.94
- : 320 shares at $0.95
- : 555 shares at $0.95
- : 490 shares at $0.96
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Immuron Ltd scorecard#
Passes 7 of the 15 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth4 of 6
- ✓Revenue grew in the newest year47.0%Revenue up 47.0% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years103.5%103.5% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median103.5%103.5% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.46 vs -1.99Diluted EPS -1.46 in fiscal 2025 against -1.99 the year before (report's currency).
- ✗Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$2 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-73.3%-73.3% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-49.2%-49.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-73.3%-73.3% in fiscal 2025 against -371.4% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities5.1×Current ratio 5.11 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-7.46Z-score -7.46 (distress zone) for fiscal 2025.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✓Share count up no more than 2% in a year1.4%Diluted shares up 1.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Immuron Ltd's statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -73.3% | -60.5% | |
| Net margin | -71.6% | -68.9% | |
| Return on equity | -49.2% | -61.0% | |
| Revenue growth, 3 years a year | 103.5% | 12.9% | |
| Revenue growth | 47.0% | 15.8% |
1of 8on the Piotroski tests of financial strength
- Net loss of $3 million, the 10th loss-making year in a row.
- Revenue has grown 4 years in a row.
Immuron Ltd: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in AUD thousands; per-share figures in AUD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Jun 30, 2025 | FY 2024to Jun 30, 2024 | FY 2023to Jun 30, 2023 | FY 2022to Jun 30, 2022 | FY 2021to Jun 30, 2021 | FY 2020to Jun 30, 2020 | FY 2019to Jun 30, 2019 | FY 2018to Jun 30, 2018 | FY 2017to Jun 30, 2017 | FY 2016to Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 7,287+48.6%100% | 4,903+172%100% | 1,805+136%100% | 765+425%100% | 146−94.2%100% | 2,519r1,899+24.9%100% | 2,016r2,387+38.4%100% | 1,457r1,843+4.3%100% | 1,396+39.5%100% | 1,001—100% | |
| Cost of revenue | 2,522+61.0%34.6% | 1,566+216%31.9% | 496+105%27.5% | 242+373%31.6% | 51−92.6%35.0% | 689+3.2%27.4% | 667+59.4%33.1% | 419+24.0%28.7% | 338+12.0%24.2% | 301—30.1% | |
| Gross profit | 4,765+42.8%65.4% | 3,337+155%68.1% | 1,309+150%72.5% | 524+453%68.4% | 95−94.8%65.0% | 1,830+6.4%72.6% | 1,720+20.8%85.3% | 1,424+34.5%97.8% | 1,059+51.3%75.8% | 700—69.9% | |
| Research and development | 3,597−33.1%49.4% | 5,375+107%110% | 2,592+294%144% | 658−51.9%86.0% | 1,367+16.0%938% | 1,179+12.8%46.8% | 1,045−53.7%51.8% | 2,257−51.3%155% | 4,631+27.8%332% | 3,624—362% | |
| Selling, general and administrative | — | — | — | — | — | — | — | 282−30.8%19.4% | 408+205%29.2% | 134—13.4% | |
| Selling and marketing | 712+110%9.8% | 339r2,030+30.7%6.9% | 260r260+5.9%14.4% | 245+43.3%32.0% | 171−27.5%117% | 236+12.6%9.4% | 210+23.8%10.4% | 169r1,094+25.2%11.6% | 135r846−85.6%9.7% | 939—93.8% | |
| General and administrative | — | — | — | — | 3,979+7.4%2729% | 3,704+0.3%147% | 3,694+176%183% | 1,337−3.3%91.7% | 1,382+4.6%99.0% | 1,321—132% | |
| Operating income | −5,345—−73.3% | −5,801—−118% | −3,569—−198% | −2,870—−375% | −8,380—−5748% | −2,906—−115% | −4,656r−4,633—−231% | −3,046r−2,988—−209% | −6,723—−482% | — | |
| Interest and finance income | 136−58.5%1.9% | 328+182%6.7% | 116+434%6.4% | 22+137%2.8% | 9.2—6.3% | — | 0.0−96.8%0.0% | 1.2−85.2%0.1% | 8.4−31.1%0.6% | 12—1.2% | |
| Interest expense and finance costs | 7.3−3.6%0.1% | 7.6−21.5%0.2% | 9.7+56.1%0.5% | 6.2−55.1%0.8% | 14−36.4%9.4% | 22—0.9% | — | 24r19−73.0%1.7% | 90r24−73.8%6.4% | 342—34.1% | |
| Provision for credit losses | — | — | −431—−23.9% | — | 760—521% | — | — | — | — | — | |
| Share of profit of associates | — | −1,456—−29.7% | −324—−18.0% | — | — | — | — | — | — | — | |
| Income before tax | −5,216—−71.6% | −6,937—−141% | −3,787—−210% | −2,854—−373% | −8,384—−5752% | −2,927—−116% | −4,656r−4,633—−231% | −3,069r−3,011—−211% | −6,804—−487% | −7,069—−706% | |
| Net income including minority interests | −5,216—−71.6% | −6,937—−141% | −3,787—−210% | −2,854—−373% | −8,384—−5752% | −2,927—−116% | −4,656r−4,633—−231% | −3,069r−3,011—−211% | −6,804—−487% | −7,069—−706% | |
| Net income attributable to shareholders | −5,216—−71.6% | −6,937—−141% | −3,787—−210% | −2,854—−373% | −8,384—−5752% | −2,927—−116% | −4,656—−231% | — | — | — | |
| Earnings per share, basic | -2.26—— | -3.04—— | -1.66—— | -1.25—— | -3.79—— | — | — | — | — | — | |
| Earnings per share, diluted | -2.26—— | -3.04—— | -1.66—— | -1.25—— | -3.79—— | — | — | — | — | — | |
| Shares, weighted average (basic) | 231+1.4%— | 228+0.0%— | 228+0.1%— | 228—— | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 231+1.4%— | 228+0.0%— | 228+0.1%— | 228—— | — | — | — | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 2,831−75.7%27.9% | 11,657−32.1%75.0% | 17,160−22.4%78.0% | 22,110−11.7%89.0% | 25,047+671%92.6% | 3,250−36.5%52.4% | 5,120+8.3%59.8% | 4,727+18.3%51.1% | 3,995+74.4%48.2% | 2,291—25.9% | |
| Short-term investments | — | — | 404—1.8% | — | — | — | — | — | — | — | |
| Receivables | 1,926+38.8%19.0% | 1,388+232%8.9% | 417−37.0%1.9% | 663+98.1%2.7% | 335+2.1%1.2% | 328−66.2%5.3% | 969−42.4%11.3% | 1,683−4.8%18.2% | 1,768—21.3% | — | |
| Inventory | 1,772+11.8%17.5% | 1,585+88.7%10.2% | 840+157%3.8% | 327+11.6%1.3% | 293−63.3%1.1% | 798+46.5%12.9% | 544+9.3%6.4% | 498−78.7%5.4% | 2,336—28.2% | — | |
| Other current assets | 3,487+3500%34.4% | 97−38.8%0.6% | 158−72.4%0.7% | 572+631%2.3% | 78+136%0.3% | 33−32.7%0.5% | 49−65.2%0.6% | 142−15.8%1.5% | 168—2.0% | — | |
| Current assets | 10,015−32.0%98.9% | 14,726−27.8%94.7% | 20,409−13.8%92.8% | 23,672−8.1%95.2% | 25,753+484%95.2% | 4,409−34.0%71.1% | 6,682−5.2%78.1% | 7,050−14.7%76.3% | 8,268—99.8% | — | |
| Property, plant and equipment | 114−26.2%1.1% | 154−22.9%1.0% | 200−11.7%0.9% | 227+572%0.9% | 34−52.3%0.1% | 71+313%1.1% | 17−15.9%0.2% | 20+8.2%0.2% | 19—0.2% | — | |
| Right-of-use (leased) assets | — | 140−22.2%0.9% | 180−13.0%0.8% | 207+964%0.8% | 19−66.5%0.1% | 58—0.9% | — | — | — | — | |
| Investments in associates | — | — | 159—0.7% | — | — | — | — | — | — | — | |
| Non-current assets | 115−86.1%1.1% | 824−47.8%5.3% | 1,579+33.4%7.2% | 1,184−9.0%4.8% | 1,300−27.5%4.8% | 1,793−4.6%28.9% | 1,879−14.3%21.9% | 2,192+11538%23.7% | 19—0.2% | — | |
| Total assets | 10,130−34.9%100% | 15,550−29.3%100% | 21,988−11.5%100% | 24,856−8.1%100% | 27,053+336%100% | 6,202−27.6%100% | 8,562−7.4%100% | 9,243+11.5%100% | 8,286−6.1%100% | 8,827—100% | |
| Accounts payable | 1,529−28.4%15.1% | 2,136+79.1%13.7% | 1,193+2.7%5.4% | 1,161+53.1%4.7% | 758+97.3%2.8% | 384−64.8%6.2% | 1,092+58.4%12.8% | 689−46.6%7.5% | 1,290—15.6% | — | |
| Current liabilities | 1,966−27.1%19.4% | 2,699+21.6%17.4% | 2,219+47.6%10.1% | 1,503+34.0%6.0% | 1,122+117%4.1% | 516−56.8%8.3% | 1,196+48.8%14.0% | 803−53.1%8.7% | 1,712—20.7% | — | |
| Lease liabilities (non-current) | — | 133−11.6%0.9% | 150−14.3%0.7% | 175—0.7% | — | 19—0.3% | — | — | — | — | |
| Non-current liabilities | 95−33.2%0.9% | 142−7.0%0.9% | 152−13.2%0.7% | 175+385%0.7% | 36−13.5%0.1% | 42+179%0.7% | 15—0.2% | — | — | — | |
| Total liabilities | 2,061−27.5%20.3% | 2,841+19.8%18.3% | 2,371+41.3%10.8% | 1,678+44.9%6.8% | 1,158+107%4.3% | 558−53.9%9.0% | 1,211+50.7%14.1% | 803−53.1%8.7% | 1,712−56.0%20.7% | 3,887—44.0% | |
| Retained earnings | −82,443—−814% | −78,968—−508% | −72,055—−328% | −68,425—−275% | −65,933—−244% | −57,916—−934% | −57,239r−56,861—−669% | −52,539—−568% | −49,528—−598% | — | |
| Total equity | 8,069−36.5%79.7% | 12,709−35.2%81.7% | 19,617−15.4%89.2% | 23,177−10.5%93.2% | 25,895+359%95.7% | 5,644−23.2%91.0% | 7,351−12.9%85.9% | 8,439+28.4%91.3% | 6,575—79.3% | — | |
| Shares outstanding | — | — | 0.0—— | — | — | — | — | 130+62.3%— | 80+6.9%— | 75—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 50+8.1%0.7% | 46−5.5%0.9% | 49+82.9%2.7% | 27−39.0%3.5% | 44−0.9%30.0% | 44+733%1.7% | 5.3+4.8%0.3% | 5.0+2.5%0.3% | 4.9+26.5%0.4% | 3.9—0.4% | |
| Share-based compensation | 304+9122%4.2% | 3.3−98.5%0.1% | 227+139%12.6% | 95—12.4% | — | 73r−534−94.6%2.9% | 1,344+2140%66.6% | 60r−60−88.5%4.1% | 523r−523—37.4% | −2,079—−208% | |
| Cash from operating activities | −6,137—−84.2% | −5,880—−120% | −2,595—−144% | −3,148—−411% | −4,079—−2798% | −3,147—−125% | −1,799—−89.2% | −3,505r−3,527—−241% | −6,942r−7,031—−497% | −5,158—−515% | |
| Capital expenditure | — | −0.2—−0.0% | −7.7—−0.4% | −10—−1.3% | −6.6—−4.5% | −0.9—−0.0% | −2.0—−0.1% | −6.6—−0.5% | −5.7—−0.4% | −2.4—−0.2% | |
| Cash from investing activities | −2,900−985%−39.8% | 328—6.7% | −2,621−22433%−145% | 12+356%1.5% | 2.6—1.8% | −0.9—−0.0% | −2.0—−0.1% | −5.3r−6.6−298%−0.4% | 2.7r−5.7—0.2% | −2.4—−0.2% | |
| Debt issued | — | — | — | — | 213—146% | — | — | 5000.0%34.3% | 500−83.1%35.8% | 2,950—295% | |
| Debt repaid | — | — | — | — | −213—−146% | −367—−14.6% | — | −866—−59.4% | −2,192—−157% | −1,077—−108% | |
| Shares issued | — | 24—0.5% | — | — | 29,281+1396%20087% | 1,957−32.4%77.7% | 2,894−47.1%144% | 5,472r5,316−56.3%376% | 12,525+404%897% | 2,483—248% | |
| Shares bought back | — | — | −79—−4.4% | — | — | — | — | — | — | — | |
| Cash from financing activities | 200+23995%2.7% | 0.8—0.0% | −45—−2.5% | −42−100%−5.5% | 26,480+2189%18165% | 1,157−44.1%45.9% | 2,069−52.4%103% | 4,349r4,373−49.5%299% | 8,604r8,701+98.5%616% | 4,335—433% | |
| Exchange-rate effect on cash | 11−78.0%0.1% | 49−84.1%1.0% | 311+28.6%17.2% | 242—31.6% | −607−598%−417% | 122−1.6%4.8% | 124—6.1% | −107−366%−7.3% | 40—2.9% | — | |
| Change in cash | −8,838—−121% | −5,552—−113% | −5,261—−292% | −3,179−114%−415% | 22,404—15369% | −1,991−841%−79.1% | 269−68.0%13.3% | 839−49.6%57.6% | 1,664—119% | −825—−82.5% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Immuron Ltd sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Travelan$5 M99%+14%
- ProIBS$0 M1.1%—
- Protectyn$0 M0.3%-33%
Business segments
- Hyper-Immune Products$5 M100%+15%
Source: SEC annual report (XBRL data) · as of Jun 30, 2026
How Immuron Ltd compares in Biotechnology
- Market cap$9 M · higher than 9% of 726
- Revenue$5 M · higher than 35% of 647
- Net margin-71.6% · higher than 47% of 408
- Revenue growth47.0% · higher than 71% of 438
- Price / sales1.9× · lower than 86% of 339
- Price / book1.7× · lower than 62% of 534
- FCF yield-42.8% · higher than 27% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Immuron Ltd🇦🇺 | $9 M | — | -71.6% | +47.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending June-2025
- Balance sheet:
- As of June-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Immuron Ltd? Verify and update this profile — free
Show Immuron Ltd's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.